Montelukast (Singulair) Linked to Psychiatric Effects by FDA Researchers

Key Insights

• FDA researchers have found that montelukast, known as Singulair, impacts multiple brain receptors critical for psychiatric function.
• The asthma drug, originally marketed by Merck & Co., is widely prescribed and also available as a generic.
• The findings suggest a potential link between montelukast and serious mental health problems, according to a Reuters report.

U.S. government researchers have identified a potential link between montelukast, commonly known as Singulair and also available generically, and serious mental health problems. The findings, stemming from a scientific presentation, indicate that the widely prescribed asthma drug, originally marketed by Merck & Co (MRK), interacts with multiple brain receptors crucial for psychiatric functioning.

This interaction raises concerns about the drug's impact on mental health, particularly given its widespread use in treating asthma and allergies. The research highlights the importance of understanding the potential neuropsychiatric effects of commonly prescribed medications.

The study suggests that montelukast's mechanism of action extends beyond its known effects on leukotriene receptors in the respiratory system, impacting neurological pathways. Further research is needed to fully elucidate the nature and extent of these psychiatric effects and to determine the clinical implications for patients taking montelukast.